LATEST ALERTS
US firm 22nd Century expects to double its total annual revenue following the acquisition of GVB Biopharma – which it describes as one of the largest global CBD suppliers – as part of a plan to rapidly grow its hemp/cannabis business.
“We are actively pursuing additional contracts in the industry to accelerate GVB’s existing growth opportunities while working to integrate our high-yield plant strains into GVB’s supply chain, further enhancing the productivity and profitability of this franchise,” said James Mish, 22nd Century Group’s CEO.
